- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01171521
Management of Complex Wounds Using a Constant Tension External Tissue Expander
Complex wounds that cannot be closed primarily are at great risk for complications. A new technique utilizing external tissue expansion holds promise in rapidly decreasing wound area. Facilitation of rapid wound closure is critical in preventing wound complications.
Hypothesis:
Using the Dermaclose Wound Management System (Woundcare Technologies, Inc., Chanhassen, MN) in complex wounds not able to be primarily closed will decrease the time to secondary closure and decrease the need for secondary soft tissue coverage procedures, or if secondary soft tissue procedures are required, its use will decrease the size and complexity of the secondary soft tissue procedures.
Null Hypothesis:
The Dermaclose system will not decrease the need, dimensions, or complexity of secondary soft tissue coverage procedures in complex wounds not able to be primarily closed.
Study Overview
Detailed Description
Upon IRB approval, 50 patients with complex soft tissue wounds, with or without an associated fracture that cannot be closed primarily will have the Dermaclose device applied and will be prospectively followed for 1 year. The Dermaclose device will be applied according to the manufacturer's guidelines. This device may be combined with the use of Negative Pressure Wound Therapy. Primary and secondary end points that were initially intended to be included are listed below. However, on SF12 and pain outcome measures were collected and reported.
Initially Intended Primary end points (only SF12 collected and reported):
SF12
- Initial and final wound dimensions
- Secondary soft tissue coverage procedures
- Dimensions and type of secondary soft tissue coverage procedures required compared to initial wound dimensions
- Method of wound closure
- Days to wound closure
- Number and types of procedures required for wound closure
- Infection requiring reoperation
- Wound dehiscence requiring reoperation
Initially intended Secondary end points (only #3 collected and reported):
- Superficial wound dehiscence not requiring reoperation
- Superficial wound infection not requiring reoperation
- Visual Analog Pain Scale (VAS) with Dermaclose use
- Use of negative pressure wound therapy
- Cost-to-benefit ratio of Dermaclose use - hospital days, number of procedures, procedural and hospital costs including device, negative pressure wound therapy costs, and operating room time and associated costs
Patients will be evaluated daily during their inpatient hospital stays for VAS related to the wound for which the Dermaclose device is used. If the Dermaclose device is used on an outpatient basis, the patient will be asked to complete a daily VAS at the same time to monitor pain associated with device use. After hospital discharge, the patients will be evaluated at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months. They will complete an SF-12 as part of the above evaluations. Patients may be evaluated at more frequent intervals if the need arises. Primary and secondary endpoints will be evaluated at each time point.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- University of Missouri Hospital and Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or greater
- Has soft tissue wound(s) that are unable to be closed primarily
Exclusion Criteria:
- Age less than 18
- Has wound(s) that can be closed primarily
- Infected wound
- Unable to comply with protocol
- Prior radiation treatment to skin or soft tissues in the area of the wound
- Friable wound margins
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DermaClose Group
DermaClose device applied to complex soft-tissue wound, with or without negative pressure wound therapy, and prospectively followed for primary and secondary outcomes for one year.
|
The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life
Time Frame: 6 months
|
The SF-12 contains 12 items from the SF-36 Health Survey - . The SF-12 contains one or two items that measure each of the eight concepts included in the SF-36. The Quality of Life SF-12 is a scale from 0 - 100, in which 0 = poor functioning and 100 = excellent functioning. |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain
Time Frame: 6 months
|
Visual Analog Pain Scale (VAS) with DermaClose use, and on study wound at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.
The scale goes from 0 to 10 with 0 being no pain and 10 being the most severe pain imaginable.
It is a visual analog scale so is continuous data.
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB1162777
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wounds and Injuries
-
3MWithdrawn
-
Centre Hospitalier Universitaire de NīmesCompletedWounds and Injuries, Hands | Wounds and Injuries, Wrists | Wounds and Injuries, Feet | Wounds and Injuries, AnklesFrance
-
Samsung Medical CenterCompletedNeedle Stick InjuriesKorea, Republic of
-
Assaf-Harofeh Medical CenterUnknownInjuries and Wounds
-
Karolinska InstitutetCompletedWounds and Injuries | Blast Injuries | War-Related Injuries | Gunshot WoundSweden
-
Hospital Universiti Sains MalaysiaActive, not recruiting
-
Medical University of South CarolinaCompletedNeedlestick InjuriesUnited States
-
Temple UniversityWithdrawnLacerations | Injuries | WoundsUnited States
-
Karolinska InstitutetMedecins Sans Frontieres, NetherlandsCompletedWounds and Injuries | Leg Injuries | Soft Tissue Injuries | Wound Infection | Arm Injuries | Wounds, Penetrating | Wounds, Gunshot | War-Related InjuriesJordan
Clinical Trials on DermaClose Group
-
Baxter Healthcare CorporationDuke UniversityRecruiting
-
University of Missouri-ColumbiaWound Care Technologies, Inc.TerminatedWounds and Injuries | Compartment SyndromeUnited States
-
University of Sao Paulo General HospitalCompletedOsteoarthritis, Knee
-
Charite University, Berlin, GermanyDepartment of Neurology, Charité - Universitätsmedizin Berlin, Germany; Department...Unknown
-
Cairo UniversityCompleted
-
Al-Azhar UniversityCompleted
-
Zagazig UniversityCompleted
-
Riphah International UniversityCompleted
-
Aqua Medical Services (Pvt) LtdCompletedLumbar Disc Herniation | Spinal Disk Injury | ProtrusionPakistan
-
ThinkWellUniversity of Oxford; Queen's University, Belfast; The BMJCompleted